Related Experiment Video

Updated: Jun 6, 2025

An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use
10:33

An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use

Published on: May 24, 2024

716

Fulzerasib: First Approval

Yvette N Lamb1

  • 1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.

Drugs
|November 25, 2024
PubMed

Insights

Fulzerasib is a new oral medication targeting KRAS G12C mutations in advanced non-small cell lung cancer (NSCLC). It recently gained approval in China for patients who have undergone prior systemic therapy.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Fulzerasib is an orally active small molecule inhibitor targeting the KRAS G12C mutant protein.
  • This mutation is a key driver in various solid tumors, including non-small cell lung cancer (NSCLC) and colorectal cancer.

Purpose of the Study:

  • To summarize the development milestones of fulzerasib.
  • To document the drug's first approval for treating KRAS G12C-mutated advanced NSCLC.

Main Methods:

  • Review of clinical development data for fulzerasib.
  • Analysis of the phase II study results supporting the drug's efficacy.

Main Results:

  • Fulzerasib received its first conditional approval in China on August 21, 2024.
  • Approval is for adults with KRAS G12C-mutated advanced NSCLC after at least one line of systemic therapy.

Conclusions:

  • Fulzerasib represents a significant advancement in targeted therapy for KRAS G12C-mutated NSCLC.
  • The drug's development highlights progress in precision medicine for oncological conditions.

More Related Videos

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-308:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

995
Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

8.3K

Related Concept Videos

Ultrasound II: Endoscopic Ultrasound and FibroScan01:25

Ultrasound II: Endoscopic Ultrasound and FibroScan

Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
78
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K